Cargando…

Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788807/ https://www.ncbi.nlm.nih.gov/pubmed/35700443 http://dx.doi.org/10.1093/rheumatology/keac326

Ejemplares similares

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
por: Furie, Richard A, et al.
Publicado: (2021)

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Askanase, Anca D., et al.
Publicado: (2021)

Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
Publicado: (2018)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
por: Werth, Victoria P, et al.
Publicado: (2021)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Correction: Development of a systemic lupus erythematosus cardiovascular risk equation
Publicado: (2020)

Correction to: Nonacog Beta Pegol: A Review in Haemophilia B
por: Syed, Yahiya Y.
Publicado: (2018)

Correction to: Damoctocog Alfa Pegol: A Review in Haemophilia A
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model
por: Cleanthous, Sophie, et al.
Publicado: (2021)

Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2008)

Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial
por: Isenberg, David, et al.
Publicado: (2014)

Correction: Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus
por: Shah, Kamini, et al.
Publicado: (2010)

Correction: Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models
por: Ceccarelli, Fulvia, et al.
Publicado: (2019)

Correction: Lipid Anti-Lipid Antibody Responses Correlate with Disease Activity in Systemic Lupus Erythematosus
por: Jovanović, Vojislav, et al.
Publicado: (2013)

Correction to: Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response
por: Lee, Joo Youn, et al.
Publicado: (2020)

Correction to: Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis
por: Zhao, Xingwang, et al.
Publicado: (2021)

Correction to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
por: Dattola, Annunziata, et al.
Publicado: (2017)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
por: Coto-Segura, Pablo, et al.
Publicado: (2023)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
por: Smolen, J S, et al.
Publicado: (2015)

Correction: Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011
por: Goss, Louisa B, et al.
Publicado: (2015)

Correction to: Evaluating the performance of ACR, SLICC and EULAR/ACR classification criteria in childhood onset systemic lupus erythematosus
por: Abdwani, Reem, et al.
Publicado: (2021)

Correction: Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program
Publicado: (2019)

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
por: Patel, Sunil S., et al.
Publicado: (2023)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Morand, Eric, et al.
Publicado: (2022)

Correction: Individualized Homeopathic Treatment and Fluoxetine for Moderate to Severe Depression in Peri- and Postmenopausal Women (HOMDEP-MENOP Study): A Randomized, Double-Dummy, Double-Blind, Placebo-Controlled Trial
Publicado: (2015)

Correction: Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study
por: Dahlgren, James, et al.
Publicado: (2007)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
por: Soriano, Enrique R, et al.
Publicado: (2018)

Erratum: Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort
Publicado: (2016)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
por: Zhang, Wenhui, et al.
Publicado: (2022)

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
por: Khamashta, Munther, et al.
Publicado: (2016)

Correction: Pregnancy outcomes in patients receiving assisted reproductive therapy with systemic lupus erythematosus: a multi-center retrospective study
por: Lao, Minxi, et al.
Publicado: (2023)

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
por: Wallace, Daniel J, et al.
Publicado: (2014)

Correction: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study
por: Djabarouti, Sarah, et al.
Publicado: (2011)

Correction: Defective Expression and Function of the Leukocyte Associated Ig-like Receptor 1 in B Lymphocytes from Systemic Lupus Erythematosus Patients
por: Colombo, Barbara M., et al.
Publicado: (2012)

Correction: Gene Network Analysis of Bone Marrow Mononuclear Cells Reveals Activation of Multiple Kinase Pathways in Human Systemic Lupus Erythematosus
por: Nakou, Magdalene, et al.
Publicado: (2013)

Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial
por: Fiechtner, JJ, et al.
Publicado: (2014)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_efis6e9smkh7upphr4k8ohclja